Accumulating evidence demonstrates that downregulation of pro-apoptotic proteins or upregulation of anti-apoptotic proteins of the BCL-2 family contributes to the resistance against currently available anti-cancer drugs [2,116]. The gene discussed is BCL2; the disease is cancer.